Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
Company profile
Ticker
ENDPQ, ENDPQ
Exchange
Website
CEO
Blaise Coleman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Endo International Ltd
SEC CIK
Corporate docs
Subsidiaries
70 Maple Avenue, LLC • Actient Pharmaceuticals LLC • Actient Therapeutics, LLC • Anchen Incorporated • Anchen Pharmaceuticals, Inc. • Astora Women's Health Bermuda ULC • Astora Women's Health Ireland Limited • Astora Women's Health, LLC • Auxilium International Holdings, LLC • Auxilium Pharmaceuticals, LLC ...
ENDPQ stock data
Latest filings (excl ownership)
10-K
2022 FY
Annual report
6 Mar 23
8-K
Endo Reports Fourth-quarter 2022 Financial Results
6 Mar 23
8-K
Other Events
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
27 Feb 23
Transcripts
ENDPQ
Earnings call transcript
2022 Q1
6 May 22
ENDPQ
Earnings call transcript
2021 Q4
1 Mar 22
ENDPQ
Earnings call transcript
2021 Q3
5 Nov 21
ENDPQ
Earnings call transcript
2021 Q2
7 Aug 21
ENDPQ
Earnings call transcript
2021 Q1
7 May 21
ENDPQ
Earnings call transcript
2020 Q4
27 Feb 21
ENDPQ
Earnings call transcript
2020 Q3
6 Nov 20
ENDPQ
Earnings call transcript
2020 Q2
6 Aug 20
ENDPQ
Earnings call transcript
2020 Q1
7 May 20
ENDPQ
Earnings call transcript
2019 Q4
26 Feb 20
Latest ownership filings
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 23
SC 13G
BlackRock Inc.
8 Sep 22
SC 13G
MILLENNIUM MANAGEMENT LLC
29 Aug 22
4
James Patrick Tursi
17 Aug 22
SC 13G
BlackRock Inc.
8 Jul 22
SC 13G
MILLENNIUM MANAGEMENT LLC
27 Jun 22
4
Patrick A Barry
31 Mar 22
4
Frank B. Raciti
31 Mar 22
4
Matthew Joseph Maletta
31 Mar 22
4
Mark T. Bradley
31 Mar 22
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.25 bn | 1.25 bn | 1.25 bn | 1.25 bn | 1.25 bn | 1.25 bn |
| Cash burn (monthly) | 11.71 mm | 31.84 mm | 79.89 mm | 240.68 mm | (no burn) | (no burn) |
| Cash used (since last report) | 32.07 mm | 87.18 mm | 218.74 mm | 659.00 mm | n/a | n/a |
| Cash remaining | 1.22 bn | 1.16 bn | 1.03 bn | 590.24 mm | n/a | n/a |
| Runway (months of cash) | 103.9 | 36.5 | 12.9 | 2.5 | n/a | n/a |
Institutional ownership, Q2 2022
58.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 150 |
| Opened positions | 11 |
| Closed positions | 69 |
| Increased positions | 41 |
| Reduced positions | 58 |
| 13F shares | Current |
|---|---|
| Total value | 80.89 mm |
| Total shares | 138.58 mm |
| Total puts | 797.40 k |
| Total calls | 346.80 k |
| Total put/call ratio | 2.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 25.39 mm | $11.82 mm |
| BLK Blackrock | 18.63 mm | $8.68 mm |
| Renaissance Technologies | 12.52 mm | $5.83 mm |
| Paulson & Co. | 7.79 mm | $3.63 mm |
| Aqr Capital Management | 6.39 mm | $2.98 mm |
| Acadian Asset Management | 6.01 mm | $2.80 mm |
| STT State Street | 4.93 mm | $2.30 mm |
| Ergoteles | 4.14 mm | $1.93 mm |
| Geode Capital Management | 4.09 mm | $1.90 mm |
| Jacobs Levy Equity Management | 3.65 mm | $1.70 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Jul 22 | Tursi James Patrick | RSU | Sale back to company | Dispose D | No | No | 0 | 280,373 | 0.00 | 0 |
| 30 Mar 22 | Coleman Blaise | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.52 | 10,137 | 25.55 k | 422,066 |
| 30 Mar 22 | Coleman Blaise | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 35,910 | 0.00 | 432,203 |
| 30 Mar 22 | Coleman Blaise | Stock Incentive Plan Performance Share Units | Option exercise | Dispose M | No | No | 0 | 89,663 | 0.00 | 1,342,584 |
| 30 Mar 22 | Mark T. Bradley | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.52 | 3,057 | 7.70 k | 101,477 |
| 30 Mar 22 | Mark T. Bradley | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 10,735 | 0.00 | 104,534 |
| 30 Mar 22 | Mark T. Bradley | Stock Incentive Plan Performance Share Units | Option exercise | Dispose M | No | No | 0 | 26,805 | 0.00 | 241,060 |
| 30 Mar 22 | Maletta Matthew Joseph | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.52 | 10,179 | 25.65 k | 351,085 |
| 30 Mar 22 | Maletta Matthew Joseph | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 34,414 | 0.00 | 361,264 |
| 30 Mar 22 | Maletta Matthew Joseph | Stock Incentive Plan Performance Share Units | Option exercise | Dispose M | No | No | 0 | 85,927 | 0.00 | 417,381 |
Press releases
Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis
13 Mar 23
Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules
10 Mar 23
ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS
6 Mar 23
Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease
6 Feb 23